Expression And Functional Implications Of TRAIL (DR4, DR5) In Acute Lymphoblastic Leukemia Before And After Chemotherapy

Purpose: To explore the expression and functional significance of death of tumornecrosis factor receptor (TRAIL) DR4, DR5in acute lymphoblastic leukemia before andafter chemotherapy and to provide new clue and fundamental experimental data for thetreatment of acute lymphoblastic leukemia.Methods: Flow cytometry (FCM) was employed to study the selected case studies of30patients, who were newly diagnosed with acute lymphoblastic leukemia patients. Amongthem,20cases of iron deficiency anemia served as the control group. We studied theexpression levels TRAIL(tumor necrosis facto-related apoptosis-inducingligand,TRAIL) of DR4and DR5、DCR1、DCR2in the leukemia cells of the bonemarrow and the peripheral blood mononuclear. Moreover, the expression levels of DR4,DR5before and after chemotherapy were compared to that in patients with irondeficiency anemia.Results: DR4and DR5remained constantly high expression levels before and afterchemotherapy when compared to the relatively lower levels of DCR1and DCR2. In themean time, chemotherapy significantly induced the expression levels of DR5, which wasmuch higher than DR4regardless of chemotherapy. Finally, the expression levels of DR4and DR5were substantially high in the30cases of acute lymphoblastic leukemia thanthat in patients with iron deficiency anemia.Conclusions: TRAIL and its receptor have differential expression patterns in acute lymphoblastic leukemia cells before and after chemotherapy. DR5may play an importantrole in TRAIL-mediated apoptosis in acute myeloid leukemia.